Colgate-Palmolive (CL) vs. Procter & Gamble (PG): Weighing Two Consumer Staples Leaders
Key Takeaways
- Relative performance: Colgate-Palmolive has outperformed the broader Consumer Staples sector over the past year, while Procter & Gamble has lagged amid cost and margin pressures.
- Growth mix: CL is benefiting from accelerating emerging-market volume, whereas PG's recent growth remains largely price-driven with flat volume.
- Valuation: Both trade at a premium to sector peers, but CL's forward price-to-earnings (P/E) multiple sits modestly higher than PG's.
- Momentum: CL is holding near its 50- and 200-day moving averages, while PG is trading below both, signaling weaker near-term trend consistency.
- Risk factors: CL faces North American softness and a personal-care divestiture process; PG faces roughly $1 billion in after-tax cost headwinds and cautious guidance.
- Sentiment: Both names carry analyst consensus ratings of "Buy," but recent earnings estimate revisions have been more favorable for CL than for PG.
Introduction
Colgate-Palmolive (CL) and Procter & Gamble (PG) remain two of the most recognizable names in global household and personal-care products. Both deliver consistent cash flow, support growing dividends, and have competed head-to-head in oral care for decades. This comparison matters for investors seeking defensive, dividend-oriented consumer staples exposure and looking to understand how the two differ in growth drivers, positioning, and recent momentum. Assessing their relative performance and risk profiles can help clarify which name might fit a particular portfolio or strategy in the current market setting.
CL Overview and Recent Performance
Colgate-Palmolive leads in oral care, personal care, home care, and pet nutrition via its Hill's brand. Recent quarters have shown improving operating momentum, with second-quarter organic sales up roughly 2.4% and organic volume turning positive as pricing growth eased. Emerging markets have driven much of the expansion, with Latin America and Asia Pacific posting mid-single-digit gains, while Hill's Pet Nutrition has continued to outpace its category.
North America has offset some of that strength, with organic sales declining due to softer category demand, retailer inventory adjustments, and increased competition. Gross margin expanded year over year, supported by pricing, mix, and productivity, though management noted higher raw-material and tariff costs ahead in the second half. Recent reports that the company is exploring a sale of certain mass-market personal-care brands, including Softsoap, Irish Spring, and Speed Stick, have introduced a potential portfolio catalyst. CL also increased its quarterly dividend, extending its long history of returns to shareholders. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
PG Overview and Recent Performance
Procter & Gamble maintains a broader portfolio across beauty, grooming, health care, fabric and home care, and baby, feminine, and family care. For fiscal 2026, the company reported net sales of roughly $87 billion, up about 3%, while organic sales rose approximately 1%—driven almost entirely by pricing, with volume and mix contributing little. Beauty stood out positively, whereas Baby, Feminine & Family Care and Health Care recorded organic declines.
Market activity has proven more challenging for PG recently. The stock has retreated from its 52-week high and trades below its 50- and 200-day moving averages, reflecting investor caution over moderating growth, ongoing commodity and logistics pressures, and a measured outlook. Management guided fiscal 2027 organic sales growth of 1% to 3% and core earnings-per-share growth of roughly flat to 3%, citing an estimated $1 billion in after-tax cost headwinds. The company continues returning substantial cash to shareholders, including a 3% dividend increase that marked its 70th consecutive annual raise.
Head-to-Head Comparison
The clearest distinction lies in scale and diversification. PG is roughly five times larger than CL by market capitalization and spans ten product categories across a wider geographic footprint, offering broader revenue diversification but also slower organic growth. CL remains more concentrated, anchored by a leading oral-care franchise (around 41% global toothpaste share) and a fast-growing pet nutrition segment that supplies a distinct growth avenue.
Growth dynamics also differ. CL's recent results reflect a healthier mix of volume and pricing, especially in emerging markets, while PG's expansion stays price-led with flat volume and pressure in value-sensitive areas. On valuation, CL's forward P/E sits slightly above PG's, though both exceed the consumer staples sector average, indicating the market still assigns a premium to these defensive franchises.
Risk profiles vary as well. CL's primary near-term concerns center on North American execution and any impact from the personal-care divestiture, whereas PG confronts heavier cost-inflation headwinds, restructuring charges, and a more cautious earnings outlook that has weighed on sentiment. From a trend standpoint, CL's ability to hold near key moving averages stands in contrast to PG's position below them, pointing to stronger relative momentum for CL in recent weeks. From what I see, this is important because it highlights differing near-term trajectories.
Tickeron AI Verdict
Based on observable factors such as trend consistency, the balance of volume- versus price-led growth, and the direction of recent earnings revisions, Tickeron's AI would likely lean toward CL in the current comparison. CL's improving volume trajectory in emerging markets, expanding gross margin, and position near its moving averages reflect more constructive technical and fundamental momentum than PG, which contends with a larger cost headwind and softer near-term trend. The advantage remains probabilistic rather than absolute: PG's superior scale, diversification, and dividend consistency continue to serve as meaningful counterweights. The AI's stance would likely favor CL for relative momentum while recognizing PG's appeal for investors who prioritize size and stability.
Using Tickeron AI Tools for Deeper Analysis
In my own review process, I often turn to Tickeron's AI tools to cross-check momentum signals and peer comparisons. One resource that stands out is the platform's curated selection of automated strategies, which helps identify approaches aligned with current market conditions and individual objectives. Reviewing published performance metrics and risk measures from these tools can provide an efficient way to supplement fundamental and technical analysis when evaluating names like CL and PG.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Momentum Indicator for CL turns positive, indicating new upward trend
CL saw its Momentum Indicator move above the 0 level on October 06, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 68 similar instances where the indicator turned positive. In 31 of the 68 cases, the stock moved higher in the following days. The odds of a move higher are at 46%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for CL just turned positive on October 06, 2026. Looking at past instances where CL's MACD turned positive, the stock continued to rise in 19 of 44 cases over the following month. The odds of a continued upward trend are 43%.
CL moved above its 50-day moving average on October 12, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +2.13% 3-day Advance, the price is estimated to grow further. Considering data from situations where CL advanced for three days, in 143 of 314 cases, the price rose further within the following month. The odds of a continued upward trend are 46%.
Bearish Trend Analysis
The RSI Indicator demonstrated that the stock has entered the overbought zone. This may point to a price pull-back soon.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 5 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CL declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 46%.
CL broke above its upper Bollinger Band on October 14, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for CL entered a downward trend on October 12, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is 8 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 12 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 45 (best 1 - 100 worst), indicating steady price growth. CL’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 52 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 89, placing this stock slightly better than average.
The Tickeron Valuation Rating of 93 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: CL's P/B Ratio (294.118) is very high in comparison to the industry average of (18.044). P/E Ratio (34.063) is within average values for comparable stocks, (43.673). Projected Growth (PEG Ratio) (1.577) is also within normal values, averaging (1.518). Dividend Yield (0.024) settles around the average of (0.024) among similar stocks. P/S Ratio (3.331) is also within normal values, averaging (1.931).
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a maker of oral, personal, and household products
Industry HouseholdPersonalCare
Advertisement